Avita Medical Shares Slide Amid Revenue Guidance Downgrade

Jan 08, 2025

Avita Medical Inc. (ASX: AVH) saw its shares drop by 15.2% following a revision of its 2024 commercial revenue guidance. The regenerative medicine company attributed the downgrade to a decline in purchasing activity, reflecting slower-than-expected market uptake. Despite this setback, Avita Medical remains focused on expanding its portfolio and driving adoption of its innovative skin-repair solutions. Investors will be watching closely as the company navigates these challenges in the year ahead.

 

 

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com